A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma
Top Cited Papers
- 27 June 2012
- journal article
- research article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 41 (2), 330-338
- https://doi.org/10.1183/09031936.00223411
Abstract
Pre-clinical data demonstrate a pivotal role for interleukin (IL)-13 in the development and maintenance of asthma. This study assessed the effects of tralokinumab, an investigational human IL-13-neutralising immunoglobulin G4 monoclonal antibody, in adults with moderate-to-severe uncontrolled asthma despite controller therapies. 194 subjects were randomised to receive tralokinumab (150, 300 or 600 mg) or placebo subcutaneously every 2 weeks. Primary end-point was change from baseline in mean Asthma Control Questionnaire score (ACQ-6; ACQ mean of six individual item scores) at week 13 comparing placebo and combined tralokinumab dose groups. Secondary end-points included pre-bronchodilator lung function, rescue β(2)-agonist use and safety. Numerical end-points are reported as mean±sd. At week 13, change from baseline in ACQ-6 was -0.76±1.04 for tralokinumab versus -0.61±0.90 for placebo (p=0.375). Increases from baseline in forced expiratory volume in 1 s (FEV(1)) were 0.21±0.38 L versus 0.06±0.48 L (p=0.072), with a dose-response observed across the tralokinumab doses tested. β(2)-agonist use (puffs per day) was decreased for tralokinumab -0.68±1.45 versus placebo -0.10±1.49 (p=0.020). The increase in FEV(1) following tralokinumab treatment remained evident 12 weeks after the final dose. Safety profile was acceptable with no serious adverse events related to tralokinumab. No improvement in ACQ-6 was observed, although tralokinumab treatment was associated with improved lung function.Keywords
This publication has 23 references indexed in Scilit:
- Preclinical development of CAT‐354, an IL‐13 neutralizing antibody, for the treatment of severe uncontrolled asthmaBritish Journal of Pharmacology, 2011
- Asthma That Is Not Well-Controlled Is Associated with Increased Healthcare Utilization and Decreased Quality of LifeJournal of Asthma, 2010
- Asthma control and activity limitations: insights from the Real-world Evaluation of Asthma Control and Treatment (REACT) StudyAnnals of Allergy, Asthma & Immunology, 2010
- Increased sputum and bronchial biopsy IL-13 expression in severe asthmaJournal of Allergy and Clinical Immunology, 2008
- Extent, patterns, and burden of uncontrolled disease in severe or difficult‐to‐treat asthmaAllergy, 2007
- Uncontrolled asthma: A review of the prevalence, disease burden and options for treatmentRespiratory Medicine, 2006
- Inhibition of human interleukin‐13‐induced respiratory and oesophageal inflammation by anti‐human‐interleukin‐13 antibody (CAT‐354)Clinical and Experimental Allergy, 2005
- Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin productionJCI Insight, 1999
- Interleukin-13: Central Mediator of Allergic AsthmaScience, 1998
- Requirement for IL-13 Independently of IL-4 in Experimental AsthmaScience, 1998